Here we report the results of the PD-L1 expression in cancer (PECan) study, which involved imaging PD-L1 using [99mTc]NM-01 SPECT/CT at baseline and 9-weeks following pembrolizumab (anti-PD-1), with or without chemotherapy, in patients with advanced NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.